Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

863 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Vermeire S, Lakatos PL, Ritter T, Hanauer S, Bressler B, Khanna R, Isaacs K, Shah S, Kadva A, Tyrrell H, Oh YS, Tole S, Chai A, Pulley J, Eden C, Zhang W, Feagan BG; LAUREL Study Group. Vermeire S, et al. Lancet Gastroenterol Hepatol. 2022 Jan;7(1):28-37. doi: 10.1016/S2468-1253(21)00295-8. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798037 Clinical Trial.
The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study.
Marchal L, D'Haens G, Van Assche G, Vermeire S, Noman M, Ferrante M, Hiele M, Bueno De Mesquita M, D'Hoore A, Penninckx F, Rutgeerts P. Marchal L, et al. Among authors: vermeire s. Aliment Pharmacol Ther. 2004 Apr 1;19(7):749-54. doi: 10.1111/j.1365-2036.2004.01904.x. Aliment Pharmacol Ther. 2004. PMID: 15043515 Free article. Clinical Trial.
Predictors of early response to infliximab in patients with ulcerative colitis.
Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Ferrante M, et al. Among authors: vermeire s. Inflamm Bowel Dis. 2007 Feb;13(2):123-8. doi: 10.1002/ibd.20054. Inflamm Bowel Dis. 2007. PMID: 17206703 Clinical Trial.
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. Clark M, et al. Among authors: vermeire s. Gastroenterology. 2007 Jul;133(1):312-39. doi: 10.1053/j.gastro.2007.05.006. Gastroenterology. 2007. PMID: 17631151
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. D'Haens G, et al. Among authors: vermeire s. Lancet. 2008 Feb 23;371(9613):660-667. doi: 10.1016/S0140-6736(08)60304-9. Lancet. 2008. PMID: 18295023 Clinical Trial.
The IL-10R1 S138G loss-of-function allele and ulcerative colitis.
Grundtner P, Gruber S, Murray SS, Vermeire S, Rutgeerts P, Decker T, Lakatos PL, Gasche C. Grundtner P, et al. Among authors: vermeire s. Genes Immun. 2009 Jan;10(1):84-92. doi: 10.1038/gene.2008.72. Epub 2008 Sep 18. Genes Immun. 2009. PMID: 18800073
863 results